CD8 TIL cell therapy - Aventis Gencell
Latest Information Update: 09 Jul 2002
At a glance
- Originator Aventis Gencell
- Class Cell therapies
- Mechanism of Action CD8 antigen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Graft-versus-host disease; Renal cancer